### Guideline Request

**Internal request:**
Review the clinical trial data on bevacizumab in the upfront and maintenance setting.

**External request:**
Submission from Genentech.

### Panel Discussion

The panel discussed the recently reported results from two phase III randomized trials. The first trial, GOG-0218, assessed carboplatin/paclitaxel/bevacizumab ± maintenance bevacizumab compared to carboplatin/paclitaxel alone in the upfront setting. The second trial, ICON7, assessed carboplatin/paclitaxel alone compared to carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab in the upfront setting. The NCCN Ovarian Cancer panel agreed that until there are more mature data from these trials, the routine addition of bevacizumab to upfront therapy with carboplatin/paclitaxel and the use of bevacizumab as maintenance therapy are not recommended.

### References


2. Perren T, Swart AM, Pfisterer J, et al. ICON7: A Phase III gynaecologic cancer interGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Presented at the 35th European Society for Medical Oncology in Milan, Italy; October 8-12, 2010. ESMO Oral Presentation.

### Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>Abstain</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>